



Marilyn W, heart transplant recipient

## CareDx at ISHLT 2022

### Leading the Way in Innovative Transplant Research

**25+** accepted abstracts involving HeartCare<sup>®</sup>, AlloSure<sup>®</sup> Heart, AlloMap<sup>®</sup> and AlloSure<sup>®</sup> Lung

Type	Title	Author/Presenter	Session Date and Time
<b>HEART</b>			
Poster	<b>Artificial Intelligence 12 Lead ECG Based Heart Age Estimation and 1-year Outcomes After Heart Transplantation</b>	Dr. Jose Ruiz Morales	Apr 27; 6:15–7:15 PM
Poster	<b>PM Variability in Donor-Derived Cell-Free DNA Levels Predicts Mortality Risk in Heart Transplant Recipients</b>	Dr. Megan Kamath	Apr 27; 6:15-7:15 PM
Poster	<b>Impact Of Donor Characteristics On AlloSure Scores</b>	SHORE data presented by Dr. Amit Alam	Apr 28; 5:15–6:15 PM
Poster	<b>Use of Donor Derived Cell Free DNA for Long Term Rejection Surveillance in OHT Recipients</b>	Dr. Swethika Sundaravel	Apr 28; 5:15–6:15 PM
Poster	<b>Early Use of Donor Derived Cell-Free DNA (dd-cfDNA) in Heart Transplantation</b>	Dr. Daniel Miklin	Apr 29; 5–6 PM
Poster	<b>Prevalence of Clinical Events Following High Donor Derived Cell Free DNA in the Absence of Rejection in Heart Transplant Recipients</b>	D-OAR data presented by Dr. Andrea Kao	Apr 29; 5–6 PM
Poster	<b>Is Absolute Change In AlloMap More Informative Than Absolute Value?</b>	SHORE data presented by Dr. Sean Pinney	Apr 29; 5–6 PM
Poster	<b>Donor Specific Allo-Antibody is Significantly Associated with Variability in Donor-Derived Cell-Free DNA Scores in Adult Heart Transplant Recipients</b>	Dr. Michelle Hickey	Apr 29; 5–6 PM
Poster	<b>Don't Take Another Piece of My Heart: Substantial Reduction in Biopsies with Initiation of Non-Invasive Rejection Surveillance at One Month Post-Transplant</b>	Dr. Erik Henricksen	Apr 29; 5–6 PM
Poster	<b>Utility of AlloMap<sup>®</sup> Scores in Younger Pediatric Heart Transplant Recipients</b>	Dr. Laura D'Addese	Apr 29; 5–6 PM

To learn more about CareDx at ISHLT 2022, please visit [www.caredx.com/isHLT2022](http://www.caredx.com/isHLT2022)

Type	Title	Author/Presenter	Session Date and Time
<b>HEART cont'd</b>			
Oral Presentation	<b>Low AlloSure® In Heartcare® Associated With Low Risk of Significant Allograft Rejection: An Analysis Of SHORE</b>	SHORE data presented by Dr. Ju Kim	Apr 29; 2:30–2:45 PM
Oral Presentation	<b>Effect Of COVID-19 Infection On HeartCare, Data From The SHORE Multicenter Registry</b>	SHORE data presented by Dr. Megan Kamath	Apr 29; 5–5:06 PM
Oral Presentation	<b>Should We Be Comforted By A “Negative” Endomyocardial Biopsy? Risk Of Future Events With Donor Derived Cell Free DNA In The Setting Of Histologic Quiescence</b>	SHORE data presented by Dr. Jeffrey Teuteberg	Apr 30; 10:30–10:45 AM
Oral Presentation	<b>Prognostic Implications And Characteristics Of Low dd-cfDNA Results In Heart Transplant Patients With Biopsy Proven Rejection</b>	SHORE data presented by Dr. Roopa Rao	Apr 30; 10:45–11 AM
Oral Presentation	<b>Impact on Donor-derived Cell-Free DNA (dd-cfDNA) of Procurement Using Paragonix Sherpapak (SP) Cardiac Transport System vs Ice Transportation</b>	Dr. Johanna van Zyl	Apr 30; 11:15-11:30 AM
Oral Presentation	<b>Relationship of Noninvasive Detection of Allograft Rejection and Injury (Donor-Derived Cell Free DNA and Gene Expression Profiling) and Tissue-Based Molecular Microscopic Diagnosis After Heart Transplantation</b>	Dr. Dae Hyun Lee	Apr 30; 11:30–11:45 AM
Oral presentation	<b>The Gut Microbiome as a Marker of Early Cardiac Allograft Injury</b>	Dr. Mark Dela Cruz	Apr 30; 12–12:15 PM
Oral Presentation	<b>Hepatitis C Donors Are Not Associated With Higher Rates Of Rejection After Cardiac Transplantation</b>	SHORE data presented by Dr. Snehal Patel	Apr 30; 12–12:15 PM
Oral Presentation	<b>Beyond the Surface: Non-Invasive Diagnostics for Rejection Surveillance</b>	Dr. Shelley Hall	Apr 30; 12–12:15 PM
Oral Presentation	<b>Effect Of CMV Viremia On HeartCare</b>	SHORE data presented by Dr. Nir Uriel	Apr 30; 12:45–1 PM
Oral presentation	<b>Using Donor-Derived Cell-Free DNA for Assessment of Myocardial Injury in Heart Transplant Recipients After SARS-CoV2 Infection</b>	Dr. Megan Kamath	Apr 30; 1–1:15 PM
Oral presentation	<b>Putting It All Together: Integrating Approaches for Rejection Assessment</b>	Dr. Eugene DePasquale	Apr 30; 1–1:15 PM
<b>LUNG</b>			
Oral Presentation	<b>Higher Levels of Donor Derived Cell Free DNA are Associated with Acute Cellular Rejection but Not with Severe PGD after Lung Transplantation</b>	Dr. Kentaro Noda	Apr 28; 11:45 AM–12 PM
Oral Presentation	<b>Bronchoalveolar Lavage Fluid (BALF) as a Compartment for Donor-Derived Cell-Free DNA (dd-cfDNA) Assessment in Lung Recipients</b>	Dr. Jamie Todd	Apr 28; 5:33–5:39 PM
Oral Presentation	<b>dd-cfDNA levels are independent of Allograft Longevity in Stable Lung Recipients</b>	Dr. Anil Trindade	Apr 28; 5:39-5:45 PM
Oral Presentation	<b>Performance of Donor-Derived Cell-Free DNA (dd-cfDNA) for Discriminating Acute Lung Allograft Injury in a Multicenter Cohort</b>	Dr. Jamie Todd	Apr 29; 8:15–8:30 AM
Oral Presentation	<b>Donor-Derived Cell-Free DNA Plus Tissue Gene Expression Profiling of Lung Allograft Injury</b>	Dr. Mena Botros	Apr 29; 8:45–9 AM
Poster	<b>Longitudinal Monitoring of Donor Derived Cell Free DNA in Lung Transplant Recipients</b>	Dr. Alice L. Gray	Apr 29; 5–6 PM